TITLE

The Endocannabinoid System: A Promising Target for the Management of Type 2 Diabetes

AUTHOR(S)
Scheen, Andr� J.
PUB. DATE
February 2009
SOURCE
Current Protein & Peptide Science;Feb2009, Vol. 10 Issue 1, p56
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Type 2 diabetes is closely related to abdominal obesity and is generally associated with other cardiometabolic risk factors, resulting in a high incidence of cardiovascular complications. Several animal and human observations suggest that the endocannabinoid (EC) system is overactivated in presence of abdominal obesity and/or diabetes, and contributes to disturbances of energy balance and metabolism. Not only it regulates the intake of nutrients through central mechanisms located within the hypothalamus and limbic area, but it also intervenes in transport, metabolism and deposit of the nutrients in the digestive tract, liver, adipose tissue, skeletal muscle, and possibly pancreas. Activation of both central and peripheral CB1 receptors promotes weight gain and associated metabolic changes. Conversely, rimonabant, the first selective CB1 receptor antagonist in clinical use, has been shown to reduce body weight, waist circumference, triglycerides, blood pressure, insulin resistance and C-reactive protein levels, and to increase HDL cholesterol and adiponectin concentrations in both non-diabetic and diabetic overweight/obese patients. In addition, a 0.5-0.7% reduction in glycated hemoglobin (HbA1c) levels was observed in metformin- or sulfonylurea-treated patients with type 2 diabetes and in drug-naive or insulin-treated diabetic patients. Almost half of metabolic changes occurred beyond weight loss, in agreement with direct peripheral effects. Rimonabant was generally well-tolerated, but with a slightly higher incidence of depressed mood disorders, anxiety, nausea and dizziness compared to placebo. New trials are supposed to confirm the potential role of rimonabant (and other CB1 neutral antagonists or inverse agonists) in overweight/obese patients with type 2 diabetes and high risk cardiovascular disease.
ACCESSION #
36560314

 

Related Articles

  • A Review of Exenatide in the Treatment of Type 2 Diabetes Mellitus. Samat, Aashish G.; Bhargava, Amit; Vasantha Reddy // Clinical Medicine Insights: Therapeutics;2010, Issue 2, p715 

    Diabetes Mellitus (DM) is a chronic disease, with a rapidly increasing worldwide incidence and prevalence. Diabetes accounts for 8% of the US population, according to the United States Centers for Disease Control and Prevention. In terms of individuals, this number comes to a staggering 24...

  • Perilipin 2 Improves Insulin Sensitivity in Skeletal Muscle Despite Elevated Intramuscular Lipid Levels. Bosma, Madeleen; Hesselink, Matthijs K. C.; Sparks, Lauren M.; Timmers, Silvie; Ferraz, Maria João; Mattijssen, Frits; van Beurden, Denis; Schaart, Gert; de Baets, Marc H.; Verheyen, Fons K.; Kersten, Sander; Schrauwen, Patrick // Diabetes;Nov2012, Vol. 61 Issue 11, p2679 

    Type 2 diabetes is characterized by excessive lipid storage in skeletal muscle. Excessive intramyocellular lipid (IMCL) storage exceeds intracellular needs and induces lipotoxic events, ultimately contributing to the development of insulin resistance. Lipid droplet (LD)--coating proteins may...

  • Incretin-Based Therapies in Patients with Type 2 Diabetes. Freeman, Jeffrey S. // Current Drug Therapy;May2010, Vol. 5 Issue 2, p75 

    Type 2 diabetes mellitus (T2DM) is a highly prevalent and progressive metabolic disease associated with significant morbidity and mortality. While glycemic control remains the cornerstone of disease treatment, successful T2DM management requires consideration of several comorbid risk factors...

  • Exenatide Improved Markers of Hepatic Function Over 3 Years in Patients With Type 2 Diabetes. Nielsen, Loretta; Xuesong Guan; Bowlus, Christopher; Holcombe, John; Maggs, David; Wintle, Matthew // Diabetes;Jun2007 Supplement 1, Vol. 56, pA149 

    Type 2 diabetes (T2D), obesity, and nonalcoholic fatty liver disease (NAFLD) are emerging public health concerns that often co-exist, with diabetes and obesity the two most important risk factors for NAFLD. Because exenatide is associated with improvement in glycemic control and weight...

  • GLYCEMIC TARGETS IN DIABETES CARE: EMERGING CLARITY AFTER ACCORD. BUSE, JOHN B. // Transactions of the American Clinical & Climatological Associati;2015, Vol. 126, p62 

    Through the 1990s convincing evidence emerged from studies involving relatively recent onset diabetes that glycemic control achieving glycated hemoglobin A1c levels of approximately 7% was associated with improved microvascular outcomes. Based on advocacy groups' statements encouraging lower...

  • ANTIDIABETIC AND ANTIHYPERLIPIDAEMIC ACTIVITY OF SEDIMENTAL EXTRACT OF TINOSPORA CORDIFOLIA IN STREPTOZOTOCIN INDUCED TYPE 2 DIABETES. KANNADHASAN, R.; VENKATARAMAN, S. // International Journal of Pharmacy & Pharmaceutical Sciences;Apr2012 Supplement 3, Vol. 4, p520 

    To study the Type 2 diabetes mediated obesity and their resurrection with SETc using preclinical evaluation. A study kept for OGTT, RBGT with SETc in normal and diabetic animals and the resulting time and dose dependant reduction in BGC were recorded in vivo. The effect of test drug among the...

  • Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes.  // Hospital Medicine Alert;Sep2013 Clinical Briefs in Primary Care, p18 

    The article discusses research on cardiovascular effects of intensive lifestyle intervention in patients with type 2 diabetes, with reference to a study published in "The New England Journal of Medicine" in 2013.

  • Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes.  // Critical Care Alert;Sep2013 Clinical Briefs In Primary Care, p18 

    The article focuses on a study conducted by the Look AHEAD research group on the effect of intensive lifestyle intervention on cardiovascular risks in Type 2 Diabetes, which was published in the "New England Journal of Medicine."

  • Intensified treatment with insulin detemir improved glycemic control, weight loss.  // Endocrine Today;Oct2011, Vol. 9 Issue 10, p20 

    The article reports that a randomized trial has found that adding insulin detemir to a treatment regimen of metformin and liraglutide resulted to improved glycemic control and sustained weight loss for up to 52 weeks in patients with type 2 diabetes.

Share

Read the Article

Other Topics